Literature DB >> 25806208

ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients.

Rakesh Bagai1, Nathan A Pennell1.   

Abstract

Entities:  

Year:  2013        PMID： 25806208      PMCID： PMC4367641          DOI： 10.3978/j.issn.2218-6751.2012.11.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

Review 1.  The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

Authors:  Josep Tabernero
Journal:  Mol Cancer Res       Date:  2007-03       Impact factor: 5.852

2.  The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer.

Authors:  Chung-Ta Lee; Nan-Haw Chow; Pei-Fang Su; Shao-Chieh Lin; Peng-Chan Lin; Jenq-Chang Lee
Journal:  Dis Colon Rectum       Date:  2008-08       Impact factor: 4.585

3.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

Review 4.  KRAS mutations in non-small cell lung cancer.

Authors:  Gregory J Riely; Jenifer Marks; William Pao
Journal:  Proc Am Thorac Soc       Date:  2009-04-15

Review 5.  Circumventing cancer drug resistance in the era of personalized medicine.

Authors:  Levi A Garraway; Pasi A Jänne
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

6.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Authors:  Richard H de Boer; Óscar Arrieta; Chih-Hsin Yang; Maya Gottfried; Valorie Chan; Johann Raats; Filippo de Marinis; Raymond P Abratt; Jürgen Wolf; Fiona H Blackhall; Peter Langmuir; Tsveta Milenkova; Jessica Read; Johan F Vansteenkiste
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

7.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Authors:  Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316

8.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

9.  Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Authors:  Fortunato Ciardiello; Roberto Bianco; Roberta Caputo; Rosa Caputo; Vincenzo Damiano; Teresa Troiani; Davide Melisi; Ferdinando De Vita; Sabino De Placido; A Raffaele Bianco; Giampaolo Tortora
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

10.  Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

Authors:  Z Tang; R Du; S Jiang; C Wu; D S Barkauskas; J Richey; J Molter; M Lam; C Flask; S Gerson; A Dowlati; L Liu; Z Lee; B Halmos; Y Wang; J A Kern; P C Ma
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.